Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARBLI vs ANCEF IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Spasticity due to multiple sclerosis,Spinal cord injury,Alcohol use disorder (off-label)
Perioperative prophylaxis,Urinary tract infections,Respiratory tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis,Off-label: Intra-amniotic infection (chorioamnionitis)
10 mg orally once daily.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (Cr Cl <10 m L/min); anephric patients up to 40 hours.
Primarily hydrolyzed by esterases to baclofen; baclofen is minimally metabolized (mainly renal clearance of unchanged drug).
Cefazolin undergoes minimal hepatic metabolism; primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
>99% bound to albumin and alpha-1-acid glycoprotein.
80-86% primarily to albumin.
0.7 L/kg, indicating extensive tissue distribution.
0.12-0.14 L/kg (8-14 L in adults); indicates limited extravascular distribution (primarily extracellular fluid).
Oral: 70% (range 60-80%); IV: 100%.
IM: 100% (complete absorption); not administered orally.
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR <30 m L/min/1.73 m²: use not recommended.
Cr Cl >55 m L/min: 1-2 g q8h; Cr Cl 35-54: 1-2 g q8h (caution); Cr Cl 11-34: 1-2 g q12h; Cr Cl <10: 1-2 g q24h (or 500 mg q12h).
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended.
No dose adjustment required for hepatic impairment. Child-Pugh classification does not alter dosing.
Not established for patients <18 years.
Infants and children: 50-100 mg/kg/day IV/IM divided q8h. Severe infections: 100 mg/kg/day, max 6 g/day.
No specific dose adjustment required; monitor renal function.
Dose based on renal function. Use lower end of dosing range due to age-related creatinine clearance decline. Monitor renal function.
Abrupt discontinuation may precipitate withdrawal reactions including seizures, hallucinations, and life-threatening hyperthermia (similar to baclofen withdrawal).
No FDA black box warning.
Risk of withdrawal symptoms with abrupt cessation,May cause sedation and dizziness,Use caution in renal impairment,May exacerbate psychiatric disorders,Avoid with alcohol or CNS depressants
Hypersensitivity reactions including anaphylaxis,Pseudomembranous colitis due to Clostridium difficile,Bleeding risk due to hypoprothrombinemia (rare),Seizures with high doses in renal impairment,Superinfection with prolonged use,Drug interactions with nephrotoxic agents (e.g., aminoglycosides)
Hypersensitivity to baclofen or any component of the formulation
Known hypersensitivity to cefazolin or other cephalosporins,Severe allergic reaction to penicillins (cross-sensitivity)
Avoid alcohol. No specific food interactions reported, but take with or without food consistently to maintain stable drug levels.
Alcohol may cause disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia) due to interference with acetaldehyde metabolism; avoid alcohol during therapy and for 48 hours after last dose. No other significant food interactions.
ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at doses up to 4 times the maximum recommended human dose based on body surface area. However, fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Based on mechanism (GABAB agonist), potential risk cannot be excluded. First trimester: unknown risk; second/third trimester: possible risk of fetal harm from maternal muscle relaxation; third trimester: risk of neonatal withdrawal (hypotonia, respiratory depression) if used near term.
Cefazolin is Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Avoid use during first trimester unless clearly needed; second and third trimester use considered safe when indicated.
No data on excretion in human milk. Arbaclofen is a small molecule (MW 215.68) and likely excreted into breast milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., sedation, respiratory depression) in nursing infants, breastfeeding is not recommended during therapy.
Cefazolin is excreted into human breast milk in low concentrations (M/P ratio approximately 0.02-0.16). Considered compatible with breastfeeding; however, monitor infant for potential gastrointestinal disturbances and sensitization.
No specific dosing guidelines established for pregnancy due to lack of data. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance) potentially requiring dose adjustments; however, no recommendations can be made because drug is contraindicated in pregnancy.
No specific dose adjustment recommended in pregnancy. Physiologic increases in plasma volume and renal clearance may theoretically reduce cefazolin concentrations, but standard dosing regimens are considered adequate for prophylaxis and treatment.
ARBLI (arbaclofen) is a prodrug of baclofen used for spasticity. Titrate slowly to avoid CNS depression. Monitor renal function; dose adjustment required in Cr Cl <60 m L/min. Avoid abrupt discontinuation due to withdrawal symptoms. Use with caution in patients with history of substance abuse due to abuse potential.
First-generation cephalosporin; administer IV/IM; adjust dose in renal impairment (Cr Cl <55 m L/min); monitor for hypersensitivity (cross-reactivity in 10% of penicillin-allergic patients); use for surgical prophylaxis (administer within 60 minutes before incision); drug of choice for MSSA infections; tissue penetration good, but CNS penetration limited unless meninges inflamed.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking abruptly; gradual dose reduction is necessary to prevent withdrawal symptoms (hallucinations, seizures, rapid heart rate).,Avoid driving or operating heavy machinery until you know how ARBLI affects you, as it may cause dizziness or drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation risk.,Inform your doctor if you have kidney problems, diabetes, or a history of substance abuse.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; complete full course even if feeling better.,Report any signs of allergic reaction (rash, itching, difficulty breathing, swelling) immediately.,Avoid alcohol during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction.,Inform healthcare provider if you have kidney disease, history of colitis, or are pregnant/breastfeeding.,Diarrhea may occur; report if severe, watery, or bloody (possible C. diff infection).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARBLI vs ANCEF IN PLASTIC CONTAINER, answered by our medical review team.
ARBLI is a Cephalosporin Antibiotic that works by ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.. ANCEF IN PLASTIC CONTAINER is a Cephalosporin Antibiotic that works by Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARBLI and ANCEF IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARBLI is: 10 mg orally once daily.. The standard adult dose of ANCEF IN PLASTIC CONTAINER is: 1-2 g IV/IM every 8 hours. Maximum 12 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARBLI and ANCEF IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARBLI is classified as Category C. ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at d. ANCEF IN PLASTIC CONTAINER is classified as Category C. Cefazolin is Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Avoid use during first trimester unless clearly. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.